Advertisement

Central European Journal of Medicine

, Volume 4, Issue 3, pp 363–368 | Cite as

Aplastic anaemia in childhood. Description of two cases and review of the literature

  • Maria Scalzone
  • Paola Coccia
  • Palma Maurizi
  • Giorgio Attinà
  • Lucia Liotti
  • Maria Giuseppina Cefalo
  • Antonio Ruggiero
  • Riccardo Riccardi
Research Article
  • 45 Downloads

Abstract

Childhood aplastic anaemia (AA) is an uncommon but potentially fatal haematological disorder. Patients with AA receive supportive care based on transfusions and timely treatment of opportunistic infections, along with specific therapies, which may be bone marrow transplantation and immunosuppressive therapy. Early diagnosis and supportive therapy are required to prevent fatal complications like overwhelming sepsis or life threatening haemorrhages. We report two cases of aplastic anaemia having a different aetiology. The diagnostic work-up and the therapeutic management for each case are described below.

Keywords

Aplastic anaemia Bone marrow transplantation Immunosuppressive therapy Supportive care 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Kojima S, Matsuyama T, Kato, S, Kigasawa H, Kobayashi R, Kikuta A., Sakamaki H, Ikuta K, Tsuchida, M., Hoshi Y, Morishima Y, Kodera Y. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002;100:799–803PubMedCrossRefGoogle Scholar
  2. [2]
    Locasciulli A. Acquired aplastic anemia in children: incidence, prognosis and treatment options. Paediatric Drugs 2002;4:761–766PubMedGoogle Scholar
  3. [3]
    Young NS. Aplastic anaemia. Lancet 1995; 346:228–832PubMedCrossRefGoogle Scholar
  4. [4]
    The International Agranulocytosis and Aplastic Anemia Study. Incidence of aplastic anemia: the relevance of diagnostic criteria. Blood 1987;70:1718–1721Google Scholar
  5. [5]
    Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze, JL, O’Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003;102:4567–4575PubMedCrossRefGoogle Scholar
  6. [6]
    Zeng W, Kajigaya S, Chen G, Risitano AM, Nunez O, Young NS. Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol, 2004;32:806–814PubMedCrossRefGoogle Scholar
  7. [7]
    Sloand E. Genetic polymorphisms and the risk of acquired idiopathic aplastic anemia. Haematologica 2005;90:1009BPubMedGoogle Scholar
  8. [8]
    Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population. Br J Haematol 2004;126:682–685PubMedCrossRefGoogle Scholar
  9. [9]
    Gidvani V, Ramkissoon S, Sloand EM, Young NS. Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol 2007;82:721–724PubMedCrossRefGoogle Scholar
  10. [10]
    Muir KR, Chilvers CE, Harriss C, et al. The role of occupational and environmental exposures in the aetiology of acquired severe aplastic anaemia: a case control investigation. Br J Haematol 2003;123:906–914PubMedCrossRefGoogle Scholar
  11. [11]
    Yanez Rubal JC, Estevez Rodriguez J, Crespo-Lopez MC, Martin- Herranz I. Carbamazepine-induced aplastic anaemia: a case report. Rev Neurol 2002;35:647–649PubMedGoogle Scholar
  12. [12]
    Brown KE, Tisdale J, Barrett AJ, Dunbar CE, Young NS. Hepatitis associated aplastic anemia. N Engl J Med. 1997;336:1059–1064PubMedCrossRefGoogle Scholar
  13. [13]
    Park CY, Kim HJ, Kim YJ, et al. Very severe aplastic anemia appearing after thymectomy. Korean J Intern Med 2003;18(1):61–63PubMedGoogle Scholar
  14. [14]
    Deka D, Malhotra N, Sinha A, Banerjee N, Kashyap R, Roy KK. Pregnancy associated aplastic anemia: maternal and fetal outcome. J Obstet Gynaecol Res 2003;29(2):67–72Google Scholar
  15. [15]
    Schrezenmeier H, Hertenstein B, Wagner B, Raghavachar A, Heimpel H. A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is suggested by a high frequency of aplastic anemia patients with a deficiency of phosphatidylinositol glycan anchored proteins. Exp Hematol 1995; 23(1):81–87PubMedGoogle Scholar
  16. [16]
    Kim I, Yoon SS, Park S, Kim BK, Kim NK. The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea. J Korean Med Sci 2003;18:365–371PubMedCrossRefGoogle Scholar
  17. [17]
    Torres HA, Bodey GP, Rolston KV, Kantarjian HM, Raad II, Kontoyiannis DP. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003;98(1):86–93PubMedCrossRefGoogle Scholar
  18. [18]
    Bhatnagar, S.K., Chandra, J., Narayan, S., Sharma, S., Singh, V. & Dutta, A.K. Pancytopenia in children: etiological profile. J Trop Pediatr 2005;51: 236–239PubMedCrossRefGoogle Scholar
  19. [19]
    Safadi R, Or R, Ilan Y, Naparstek E, Nagler A, Klein A, et al. Lack of known hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone marrow transplantation. Bone Marrow Transplant 2001;27:183–190PubMedCrossRefGoogle Scholar
  20. [20]
    Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol. 2000;111:30–42PubMedCrossRefGoogle Scholar
  21. [21]
    Locasciulli, A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, et al. Outcome of patients with acquired aplastic anaemia given first line bone marrow transplantation or immunosuppression treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92:10–17CrossRefGoogle Scholar
  22. [22]
    Ades L, Mary JY, Robin M, Ferry C, Porcher R, Esperou H, et al. Long-term outcome after bone marrow transplantation for severe aplastic anaemia. Blood 2004;103:2490–2497PubMedCrossRefGoogle Scholar
  23. [23]
    Kahl C, Leisenring W, Deeg HJ, Chauncey TR, Flowers ME, Martin PJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long term follow up. Br J Haematol 2005;130:747–751PubMedCrossRefGoogle Scholar
  24. [24]
    Champlin RE, Perez WS, Passweg J, Klein JP, Camitta BM, Gluckman E, et al. Addition of antithymocyte globulin (ATG) to cyclophosphamide (Cy) for HLA-identical sibling allogeneic bone marrow transplantation (BMT) for severe aplastic anaemia (SAA): results of a randomized controlled trial. Blood 2003;269aGoogle Scholar
  25. [25]
    Fouladi M, Herman R, Rolland-Grinton M, et al. Improved survival in severe acquired aplastic anemia in childhood. Bone Marrow Transplant 2000;26:1149–1156PubMedCrossRefGoogle Scholar
  26. [26]
    Kojima S, Horibe K, Inaba J, et al. Long-term outcome of acquired aplastic anemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000;111:321–328PubMedCrossRefGoogle Scholar
  27. [27]
    Schrezenmeier H, Marin P, Raghavachar A, McCann S, Hows J, Gluckman E, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol 1993;85:371–377PubMedCrossRefGoogle Scholar
  28. [28]
    Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. The German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11- year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236–1242PubMedCrossRefGoogle Scholar
  29. [29]
    Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000;37:91–101PubMedCrossRefGoogle Scholar
  30. [30]
    Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between haematologic response and long-term outcome. JAMA 2003;289:1130–1135PubMedCrossRefGoogle Scholar
  31. [31]
    Scheinberg P, Nunez O, Young R. Re-treatment with rabbit antithymocyte globulin and cyclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133:622–627PubMedCrossRefGoogle Scholar
  32. [32]
    Marsh JC, Socie G, Schrezenmeier H, Tichelli A, Gluckman E, Ljungman P, et al. Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet 1994;344:172–173PubMedCrossRefGoogle Scholar
  33. [33]
    Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response and survival or severe aplastic anemia patients treated with immunosuppression. ASH Annual Meeting Abstracts 2007;110:504aGoogle Scholar
  34. [34]
    Fang JP, Xu HG, Huang SL, Chen C, Huang K. Immunosuppressive treatment of aplastic anemia in Chinese children with antithymocyte globulin and cyclosporine. Pediatr Hematol Oncol 2006;23:45–50PubMedCrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Maria Scalzone
    • 1
  • Paola Coccia
    • 1
  • Palma Maurizi
    • 1
  • Giorgio Attinà
    • 1
  • Lucia Liotti
    • 1
  • Maria Giuseppina Cefalo
    • 1
  • Antonio Ruggiero
    • 1
  • Riccardo Riccardi
    • 1
  1. 1.Division of Paediatric OncologyCatholic University of RomeRomeItaly

Personalised recommendations